{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T11:33:59Z","timestamp":1791545639100,"version":"4.3.4"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2002,7,1]],"date-time":"2002-07-01T00:00:00Z","timestamp":1025481600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2002,7,1]],"date-time":"2002-07-01T00:00:00Z","timestamp":1025481600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2002,7]]},"DOI":"10.1023\/a:1016121822916","type":"journal-article","created":{"date-parts":[[2002,12,29]],"date-time":"2002-12-29T02:21:22Z","timestamp":1041128482000},"page":"177-185","source":"Crossref","is-referenced-by-count":32,"title":["Overview of the Pharmacology of the Aromatase Inactivator Exemestane"],"prefix":"10.1007","volume":"74","author":[{"given":"Robert W.","family":"Brueggemeier","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"399060_CR1","first-page":"147","volume":"354","author":"ME Lippman","year":"1990","unstructured":"Lippman ME, Dickson RB: Growth control of normal and ma-lignant breast epithelium. Prog Clin Biol Res 354: 147\u2013178, 1990","journal-title":"Prog Clin Biol Res"},{"key":"399060_CR2","doi-asserted-by":"crossref","first-page":"604","DOI":"10.3109\/07357909809032891","volume":"16","author":"PL Carmichael","year":"1998","unstructured":"Carmichael PL: Mechanisms of action of antiestrogens: relev-ance to clinical benefits and risks. Cancer Invest 16: 604\u2013611, 1998","journal-title":"Cancer Invest"},{"key":"399060_CR3","doi-asserted-by":"crossref","first-page":"2933","DOI":"10.1021\/jm00173a001","volume":"33","author":"PA Cole","year":"1990","unstructured":"Cole PA, Robinson CH: Mechanism and inhibition of cyto-chrome P-450 aromatase. J Med Chem 33: 2933\u20132942, 1990","journal-title":"J Med Chem"},{"key":"399060_CR4","doi-asserted-by":"crossref","first-page":"101","DOI":"10.3109\/14756369009040731","volume":"4","author":"RW Brueggemeier","year":"1990","unstructured":"Brueggemeier RW: Biochemical and molecular aspects of aromatase. J Enzyme Inhibit 4: 101\u2013110, 1990","journal-title":"J Enzyme Inhibit"},{"key":"399060_CR5","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1210\/endo-100-6-1684","volume":"100","author":"AM Brodie","year":"1977","unstructured":"Brodie AM, Schwarzel WC, Shaikh AA, Brodie HJ: The effect of an aromatase inhibitor, 4-hydroxy-4-androstene-3, 17-dione, on estrogen-dependent processes in reproduction and breast cancer. Endocrinology 100: 1684\u20131695, 1977","journal-title":"Endocrinology"},{"key":"399060_CR6","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1093\/annonc\/5.suppl_4.S3","volume":"5","author":"M Dowsett","year":"1994","unstructured":"Dowsett M: Aromatase inhibition: basic concepts, and the pharmacodynamics of formestane. Ann Oncol 5: S3\u20135, 1994","journal-title":"Ann Oncol"},{"key":"399060_CR7","doi-asserted-by":"crossref","first-page":"S39","DOI":"10.1023\/A:1006088405721","volume":"49","author":"M Dowsett","year":"1998","unstructured":"Dowsett M: Theoretical considerations for the ideal aromatase inhibitor. Breast Cancer Res Treat 49: S39\u201344, 1998; discus-sion S73-37","journal-title":"Breast Cancer Res Treat"},{"key":"399060_CR8","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1177\/030089169608200501","volume":"82","author":"E Bajetta","year":"1996","unstructured":"Bajetta E, Celio L, Buzzoni R, Bichisao E: Novel non-steroidal aromatase inhibitors: are there new perspectives in the treatment of breast cancer? Tumori 82: 417\u2013422, 1996","journal-title":"Tumori"},{"key":"399060_CR9","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S0960-0760(97)80008-8","volume":"61","author":"G Shetty","year":"1997","unstructured":"Shetty G, Krishnamurthy H, Krishnamurthy HN, Bhatnagar S, Moudgal RN: Effect of estrogen deprivation on the repro-ductive physiology of male and female primates. J Steroid Biochem Mol Biol 61: 157\u2013166, 1997","journal-title":"J Steroid Biochem Mol Biol"},{"key":"399060_CR10","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/0960-0760(94)90270-4","volume":"49","author":"E di Salle","year":"1994","unstructured":"Di Salle E, Briatico G, Giudici D, Ornati G, Zaccheo T, Buzzetti F, Nesi M, Panzeri A: Novel aromatase and 5 alpha-reductase inhibitors. J Steroid Biochem Mol Biol 49: 289\u2013294, 1994","journal-title":"J Steroid Biochem Mol Biol"},{"key":"399060_CR11","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/BF00682739","volume":"30","author":"RW Brueggemeier","year":"1994","unstructured":"Brueggemeier RW: Aromatase inhibitors-mechanisms of steroidal inhibitors. Breast Cancer Res Treat 30: 31\u201342, 1994","journal-title":"Breast Cancer Res Treat"},{"key":"399060_CR12","first-page":"619","volume":"24","author":"PE Goss","year":"1986","unstructured":"Goss PE, Jarman M, Wilkinson JR, Coombes RC: Metabolism of the aromatase inhibitor 4-hydroxyandrostenedione in vivo. Identification of the glucuronide as a major urinary metabolite in patients and biliary metabolite in the rat. J Steroid Biochem 24: 619\u2013622, 1986","journal-title":"Identification of the glucuronide as a major urinary metabolite in patients and biliary metabolite in the rat. J Steroid Biochem"},{"key":"399060_CR13","doi-asserted-by":"crossref","first-page":"292","DOI":"10.2165\/00002512-199609040-00006","volume":"9","author":"LR Wiseman","year":"1996","unstructured":"Wiseman LR, Goa KL: Formestane. A review of its pharma-cological properties and clinical efficacy in the treatment of postmenopausal breast cancer. Drugs Aging 9: 292\u2013306, 1996","journal-title":"Drugs Aging"},{"key":"399060_CR14","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/0022-4731(88)90129-X","volume":"30","author":"D Giudici","year":"1988","unstructured":"Giudici D, Ornati G, Briatico G, Buzzetti F, Lombardi P, di Salle E: 6-Methylenandrosta-1,4-diene-3,17-dione (FCE 24304): a new irreversible aromatase inhibitor. J Steroid Biochem 30: 391\u2013394, 1988","journal-title":"J Steroid Biochem"},{"key":"399060_CR15","first-page":"5933","volume":"52","author":"TR Evans","year":"1992","unstructured":"Evans TR, Di Salle E, Ornati G, Lassus M, Benedetti MS, Pianezzola E, Coombes RC: Phase I and endocrine study of exemestane (FCE 24304), a new aromatase inhibitor, in postmenopausal women. Cancer Res 52: 5933\u20135939, 1992","journal-title":"Cancer Res"},{"key":"399060_CR16","doi-asserted-by":"crossref","first-page":"S45","DOI":"10.1023\/A:1006048722559","volume":"49","author":"PE Lonning","year":"1998","unstructured":"Lonning PE: Pharmacological profiles of exemestane and formestane, steroidal aromatase inhibitors used for treatment of postmenopausal breast cancer. Breast Cancer Res Treat 49: S45\u201352, 1998","journal-title":"Breast Cancer Res Treat"},{"key":"399060_CR17","first-page":"2089","volume":"4","author":"J Geisler","year":"1998","unstructured":"Geisler J, King N, Anker G, Ornati G, Di Salle E, Lonning PE, Dowsett M: In vivo inhibition of aromatization by exemestane, a novel irreversible aromatase inhibitor, in postmenopausal breast cancer patients. Clin Cancer Res 4: 2089\u20132093, 1998.","journal-title":"Clin Cancer Res"},{"key":"399060_CR18","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1038\/bjc.1996.531","volume":"74","author":"J Geisler","year":"1996","unstructured":"Geisler J, King N, Dowsett M, Ottestad L, Lundgren S, Walton P, Kormeset PO, Lonning PE: Influence of anastrozole (Ar-imidex), a selective, non-steroidal aromatase inhibitor, on in vivo aromatisation and plasma oestrogen levels in postmeno-pausal women with breast cancer. Br J Cancer 74: 1286\u20131291, 1996","journal-title":"Br J Cancer"},{"key":"399060_CR19","first-page":"1511","volume":"1","author":"M Dowsett","year":"1995","unstructured":"Dowsett M, Jones A, Johnston SR, Jacobs S, Trunet P, Smith IE: In vivo measurement of aromatase inhibition by letrozole (CGS 20267) in postmenopausal patients with breast cancer. Clin Cancer Res 1: 1511\u20131515, 1995","journal-title":"Clin Cancer Res"},{"key":"399060_CR20","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1111\/j.1749-6632.1990.tb34309.x","volume":"595","author":"E di Salle","year":"1990","unstructured":"Di Salle E, Giudici D, Briatico G, Ornati G: Novel irreversible aromatase inhibitors. Ann N Y Acad Sci 595: 357\u2013367, 1990","journal-title":"Ann N Y Acad Sci"},{"key":"399060_CR21","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/0039-128X(93)90029-M","volume":"58","author":"F Buzzetti","year":"1993","unstructured":"Buzzetti F, Di Salle E, Longo A, Briatico G: Synthesis and aromatase inhibition by potential metabolites of exemestane (6-methylenandrosta-1,4-diene-3,17-dione). Steroids 58: 527\u2013532, 1993","journal-title":"Steroids"},{"key":"399060_CR22","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/0960-0760(92)90198-R","volume":"43","author":"E di Salle","year":"1992","unstructured":"Di Salle E, Ornati G, Giudici D, Lassus M, Evans TR, Coombes RC: Exemestane (FCE 24304), a new steroidal aro-matase inhibitor. J Steroid Biochem Mol Biol 43: 137\u2013143, 1992","journal-title":"J Steroid Biochem Mol Biol"},{"key":"399060_CR23","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/S0959-8049(96)00494-7","volume":"33","author":"E Bajetta","year":"1997","unstructured":"Bajetta E, Zilembo N, Noberasco C, Martinetti A, Mariani L, Ferrari L, Buzzoni R, Greco M, Bartoli C, Spagnoli I, Danesini GM, Artale S, Paolini J: The minimal effective exemestane dose for endocrine activity in advanced breast cancer. Eur J Cancer 33: 587\u2013591, 1997","journal-title":"Eur J Cancer"},{"key":"399060_CR24","doi-asserted-by":"crossref","first-page":"38","DOI":"10.3109\/02841869609083966","volume":"35","author":"PE Lonning","year":"1996","unstructured":"Lonning PE: Aromatase inhibition for breast cancer treatment. Acta Oncol 35: 38\u201343, 1996","journal-title":"Acta Oncol"},{"key":"399060_CR25","first-page":"2089","volume":"4","author":"J Geisler","year":"1998","unstructured":"Geisler J, King N, Anker G, Ornati G, Di Salle E, Lonning PE, Dowsett M: In vivo inhibition of aromatization by exemestane, a novel irreversible aromatase inhibitor, in postmenopausal breast cancer patients. Clin Cancer Res 4: 2089\u20132093, 1998","journal-title":"Clin Cancer Res"},{"key":"399060_CR26","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1677\/erc.0.0060187","volume":"6","author":"WR Miller","year":"1999","unstructured":"Miller WR: Biology of aromatase inhibitors: pharmaco-logy\/ endocrinology within the breast. Endocr Relat Cancer 6: 187\u2013195, 1999","journal-title":"Endocr Relat Cancer"},{"key":"399060_CR27","first-page":"1101","volume":"3","author":"DC Johannessen","year":"1997","unstructured":"Johannessen DC, Engan T, Di Salle E, Zurlo MG, Paolini J, Ornati G, Piscitelli G, Kvinnsland S, Lonning PE:Endocrine and clinical effects of exemestane (PNU 155971), a novel steroidal aromatase inhibitor, in postmenopausal breast cancer patients: a phase I study. Clin Cancer Res 3: 1101\u20131108, 1997","journal-title":"Clin Cancer Res"},{"key":"399060_CR28","first-page":"303","volume-title":"Sex Hormones and Antihormones in Endocrine De-pendent Pathology: Basic and Clinical Aspects","author":"E di Salle","year":"1994","unstructured":"Di Salle E, Ornati G, Paridaens R, Coombes RC, Lobelle JP, Zurlo MG: Preclinical and clinical pharmacology of the aromatase inhibitor exemestane (FCE 24304). In: Motta MS, M (ed), Sex Hormones and Antihormones in Endocrine De-pendent Pathology: Basic and Clinical Aspects.Elsevier, Amsterdam, 1994, pp. 303\u2013310"},{"key":"399060_CR29","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1038\/bjc.1995.451","volume":"72","author":"N Zilembo","year":"1995","unstructured":"Zilembo N, Noberasco C, Bajetta E, Martinetti A, Mariani L, Orefice S, Buzzoni R, Di Bartolomeo M, Di Leo A, Laffran-chi A, Di Salle E: Endocrinological and clinical evaluation of exemestane, a new steroidal aromatase inhibitor. Br J Cancer 72: 1007\u20131012, 1995","journal-title":"Br J Cancer"},{"key":"399060_CR30","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/BF00682742","volume":"30","author":"M Dowsett","year":"1994","unstructured":"Dowsett M Coombes RC: Second generation aromatase in-hibitor-4-hydroxyandrostenedione. Breast Cancer Res Treat 30: 81\u201387, 1994","journal-title":"Breast Cancer Res Treat"},{"key":"399060_CR31","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1200\/JCO.2000.18.7.1399","volume":"18","author":"M Kaufmann","year":"2000","unstructured":"Kaufmann M, Bajetta E, Dirix LY, Fein LE, Jones SE, Zilembo N, Dugardyn JL, Nasurdi C, Mennel RG, Cervek J, Fowst C, Polli A, di Salle E, Arkhipov A, Piscitelli G, Miller LL, Massimini G: Exemestane is superior to megestrol acet-ate after tamoxifen failure in postmenopausal women with advanced breast cancer: results of a phase III randomized double-blind trial. The Exemestane Study Group. J Clin Oncol 18: 1399\u20131411, 2000","journal-title":"J Clin Oncol"},{"key":"399060_CR32","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1016\/0022-4731(84)90148-1","volume":"20","author":"JO Johnston","year":"1984","unstructured":"Johnston JO, Wright CL, Metcalf BW: Time-dependent inhib-ition of aromatase in trophoblastic tumor cells in tissue culture. J Steroid Biochem 20: 1221\u20131226, 1984","journal-title":"J Steroid Biochem"},{"key":"399060_CR33","first-page":"3652","volume":"50","author":"RW Brueggemeier","year":"1990","unstructured":"Brueggemeier RW, Katlic NE: Aromatase inhibition by an enzyme-activated irreversible inhibitor in human carcinoma cell cultures. Cancer Res 50: 3652\u20133656, 1990","journal-title":"Cancer Res"},{"key":"399060_CR34","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/S0960-0760(97)00072-1","volume":"63","author":"W Yue","year":"1997","unstructured":"Yue W, Brodie AM: Mechanisms of the actions of aromatase inhibitors 4-hydroxyandrostenedione, fadrozole, and amino-glutethimide on aromatase in JEG-3 cell culture. J Steroid Biochem Mol Biol 63: 317\u2013328, 1997","journal-title":"J Steroid Biochem Mol Biol"},{"key":"399060_CR35","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1677\/erc.0.0060211","volume":"6","author":"N Harada","year":"1999","unstructured":"Harada N, Honda SI, Hatano O: Aromatase inhibitors and enzyme stability. Endocr Relat Cancer 6: 211\u2013218, 1999","journal-title":"Endocr Relat Cancer"},{"key":"399060_CR36","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1677\/erc.0.0060149","volume":"6","author":"S Chen","year":"1999","unstructured":"Chen S, Zhou D, Okubo T, Kao YC, Yang C: Breast tumor aro-matase: functional role and transcriptional regulation. Endocr Relat Cancer 6: 149\u2013156, 1999","journal-title":"Endocr Relat Cancer"},{"key":"399060_CR37","doi-asserted-by":"crossref","first-page":"S68","DOI":"10.3816\/CBC.2000.s.013","volume":"1","author":"J Soudon","year":"2000","unstructured":"Soudon J: Comparison of in vitro exemestane activity versus other antiaromatase agents. Clin Breast Cancer 1: S68-S73, 2000","journal-title":"Clin Breast Cancer"},{"key":"399060_CR38","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.3816\/CBC.2000.s.002","volume":"1","author":"WR Miller","year":"2000","unstructured":"Miller WR, Dixon JM: Antiaromatase agents: preclinical data and neoadjuvant therapy. Clin Breast Cancer 1: S9-S14, 2000","journal-title":"Clin Breast Cancer"},{"key":"399060_CR39","first-page":"3307s","volume":"42","author":"C Longcope","year":"1982","unstructured":"Longcope C: Methods and results of aromatization studies in vivo. Cancer Res 42: 3307s-3311s, 1982","journal-title":"Cancer Res"},{"key":"399060_CR40","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1210\/jcem-43-4-785","volume":"43","author":"HU Schweikert","year":"1976","unstructured":"Schweikert HU, Milewich L, Wilson JD: Aromatization of androstenedione by cultured human fibroblasts. J Clin Endo-crinol Metab 43: 785\u2013795, 1976","journal-title":"J Clin Endo-crinol Metab"},{"key":"399060_CR41","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/0022-4731(79)90514-4","volume":"10","author":"E Perel","year":"1979","unstructured":"Perel E, Killinger DW: The interconversion and aromatization of androgens by human adipose tissue. J Steroid Biochem 10: 623\u2013627, 1979","journal-title":"J Steroid Biochem"},{"key":"399060_CR42","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/bjc.1976.13","volume":"33","author":"WR Miller","year":"1976","unstructured":"Miller WR, Forrest AP: Oestradiol synthesis from C19 ster-oids by human breast cancers. Br J Cancer 33: 116\u2013118, 1976","journal-title":"Br J Cancer"},{"key":"399060_CR43","first-page":"2900","volume":"45","author":"AA van Landeghem","year":"1985","unstructured":"van Landeghem AA, Poortman J, Nabuurs M, Thijssen JH: Endogenous concentration and subcellular distribution of es-trogens in normal and malignant human breast tissue. Cancer Res 45: 2900\u20132906, 1985","journal-title":"Cancer Res"},{"key":"399060_CR44","doi-asserted-by":"crossref","first-page":"3418","DOI":"10.1200\/JCO.1999.17.11.3418","volume":"17","author":"S Jones","year":"1999","unstructured":"Jones S, Vogel C, Arkhipov A, Fehrenbacher L, Eisenberg P, Cooper B, Honig S, Polli A, Whaley F, Di Salle E, Tiffany J, Consonni A, Miller L: Multicenter, phase II trial of ex-emestane as third-line hormonal therapy of postmenopausal women with metastatic breast cancer. Aromasin Study Group. J Clin Oncol 17: 3418\u20133425, 1999","journal-title":"J Clin Oncol"},{"key":"399060_CR45","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1016\/S0959-8049(97)00283-9","volume":"33","author":"B Thurlimann","year":"1997","unstructured":"Thurlimann B, Paridaens R, Serin D, Bonneterre J, Roche H, Murray R, di Salle E, Lanzalone S, Zurlo MG, Piscitelli G: Third-line hormonal treatment with exemestane in post-menopausal patients with advanced breast cancer progressing on aminoglutethimide: a phase II multicentre multinational study. Exemestane Study Group. Eur J Cancer 33: 1767\u20131773, 1997","journal-title":"Exemestane Study Group. Eur J Cancer"},{"key":"399060_CR46","doi-asserted-by":"crossref","first-page":"2234","DOI":"10.1200\/JCO.2000.18.11.2234","volume":"18","author":"PE Lonning","year":"2000","unstructured":"Lonning PE, Bajetta E, Murray R, Tubiana-Hulin M, Eisenberg PD, Mickiewicz E, Celio L, Pitt P, Mita M, Aaronson NK, Fowst C, Arkhipov A, di Salle E, Polli A, Massimini G: Activity of exemestane in metastatic breast can-cer after failure of nonsteroidal aromatase inhibitors: a phase II trial. J Clin Oncol 18: 2234\u20132244, 2000","journal-title":"J Clin Oncol"},{"key":"399060_CR47","first-page":"52","volume":"64","author":"R Paridaens","year":"2000","unstructured":"Paridaens R, Dirix L, Lohrisch C, Beex L, Nooij M, Cameron D, Biganzoli L, Cufer T, Yague C, Lobelle JP, Piccart M: Activity and safety of exemestane (E) as first-line hormonal therapy (HT) in metastatic breast cancer (MBC) patients (PT) (abstract). Breast Cancer Res Treat 64: 52a, 2000","journal-title":"Breast Cancer Res Treat"},{"key":"399060_CR48","unstructured":"Dirix L, Piccart MJ, Lohrisch C, Beex L, Nooij M, Cameron D, Biganzoli L, Cufer T, Yague C, Duchateau L, Lobelle JP, Paridaens R: Efficacy of and tolerance to exemestane (E) versus tamoxifen (T) in 1st line hormone therapy (HT) of postmenopausal metastatic breast cancer (MBC) patients (pts): a European Organisation for the Research and Treatment on Cancer (EORTC Breast Group) phase II trial with Pharmacia and Upjohn. Proc Am Soc Clin Oncol 21: 2001."},{"key":"399060_CR49","doi-asserted-by":"crossref","unstructured":"Tedeschi M, Kvinnsland S, Jones SE, Kaufmann M, Polli A, Fowst C, Massimini G: Hormonal therapy in breast cancer and predominant visceral disease: effectiveness of the new oral aromatase inactivator, Aromasin (exemestane), in advanced breast cancer patients having progressed on antiestrogens (abstract). Presented at ECCO 1999","DOI":"10.1016\/S0959-8049(99)81686-4"},{"key":"399060_CR50","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1200\/JCO.2001.19.3.881","volume":"19","author":"PE Goss","year":"2001","unstructured":"Goss PE, Strasser K: Aromatase Inhibitors in the Treatment and Prevention of Breast Cancer. J Clin Oncol 19: 881\u2013894, 2001","journal-title":"J Clin Oncol"},{"key":"399060_CR51","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/bjc.1996.94","volume":"73","author":"RA Yates","year":"1996","unstructured":"Yates RA, Dowsett M, Fisher GV, Selen A, Wyld PJ: Arimidex (ZD1033): a selective, potent inhibitor of aromatase in postmenopausal female volunteers. Br J Cancer 73: 543\u2013548, 1996","journal-title":"Br J Cancer"},{"key":"399060_CR52","first-page":"324","volume":"77","author":"TJ Iveson","year":"1993","unstructured":"Iveson TJ, Smith IE, Ahern J, Smithers DA, Trunet PF, Dowsett M: Phase I study of the oral nonsteroidal aromatase inhibitor CGS 20267 in healthy postmenopausal women. J Clin Endocrinol Metab 77: 324\u2013331, 1993","journal-title":"J Clin Endocrinol Metab"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1023\/A:1016121822916.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1023\/A:1016121822916\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.springerlink.com\/index\/pdf\/10.1023\/A:1016121822916","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1023\/A:1016121822916.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,21]],"date-time":"2025-06-21T04:21:49Z","timestamp":1750479709000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1023\/A:1016121822916"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,7]]},"references-count":52,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2002,7]]}},"alternative-id":["399060"],"URL":"https:\/\/doi.org\/10.1023\/a:1016121822916","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2002,7]]}}}